WEST HAVEN, Conn.--(BUSINESS WIRE)--May 19, 2008 - NanoViricides,
Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has received
positive initial results from the animal trials of its drug
candidates for the treatment of epidemic keratoconjunctivitis
(EKC), a severe viral infection of the eye. Evidence of significant
effectiveness was clinically observed in treated infected eyes.

"We were very pleased with the rapid response to treatment, and
we had the opportunity to observe the excellent clinical response
ourselves," said Eugene Seymour, MD, MPH, CEO of the Company. "The
clinical results we observed are far superior to any data reported
in the literature," said Anil R. Diwan, PhD, President of the
Company.

The EKC study which is designed with a duration of four weeks,
is currently in progress at a major medical center. Analysis of
biological samples is expected to take several weeks following the
completion of the study. The Company plans to make preliminary
results available publicly as they are obtained.

There are approximately 5 million cases annually of this disease
in the US, Europe and Japan. No adequate treatment exists at
present. The infection causes severe pain, blurriness of vision and
occasional blindness. While the Company currently has no approved
product for the treatment of EKC and viral conjunctivitis, the
Company projects the market for EKC and viral conjunctivitis may be
several billion dollars annually.

The Company has now shown that two of its broad-spectrum
nanoviricide drug candidates have excellent efficacies against
substantially different virus types. We have now shown these
nanoviricides to be very effective against certain non-enveloped
viruses such as the EKC-causing adenovirus. Previously we have
shown them to be highly effective against common influenza, bird
flu (H5N1), rabies, and Ebola virus.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
viral therapy. The Company's novel nanoviricide(TM) class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H5N1 bird flu,
seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever,
and Ebola virus, among others.

This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Forward-looking statements involve risks and uncertainties. Actual
events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These forward
looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause actual results,
performance, or achievements of the company to be different from
those expressed or implied including the success of the Company's
research and development efforts, the availability of adequate
financing, the successful and timely completion of clinical studies
and the uncertainties related to the regulatory process, described
in the "Management's Discussion and Analysis" section of the
Company's Form 10-KSB and other reports and filings with the
Securities and Exchange Commission.